AM-2-19

AM-2-19 is an experimental antifungal drug based on amphotericin B (AmB) that is engineered to be less toxic to the kidneys. Amphotericin B, a polyene group of molecule targets fungal ergosterol as well as human cholesterol, results in kidney damage. While AM-2-19 or SF001, initially developed by Sfunga Therapeutics, and now being developed by Elion Therapeutics, not only selective to fungal ergosterol but also draws out fungal ergosterol more effectively. The investigational new drug (IND) application was filed in May 2023. SF001 received Qualified Infectious Disease Product (QIDP) for invasive aspergillosis and Fast Track designations from the FDA in 2023. It is now under phase I trial. An oral formulation is currently in the feasibility phase.